Something went wrong with the connection!

Epidermal Growth Factor Receptor (EGFR) Inhibitors-Induced Skin Disorders Market to Register Stunning Growth During the Forecast Period (2022-2032), Predicts DelveInsight

 Breaking News
  • No posts were found

Epidermal Growth Factor Receptor (EGFR) Inhibitors-Induced Skin Disorders Market to Register Stunning Growth During the Forecast Period (2022-2032), Predicts DelveInsight

December 08
13:58 2022
Epidermal Growth Factor Receptor (EGFR) Inhibitors-Induced Skin Disorders Market to Register Stunning Growth During the Forecast Period (2022-2032), Predicts DelveInsight
Delveinsight Business Research LLP
As per DelveInsight, the EGFR Inhibitors-Induced Skin Disorders therapeutics market is expected to grow in the coming years owing to the increasing disease prevalence and the potential launch of novel medical therapies in the market.

The EGFR Inhibitors-Induced Skin Disorders pipeline possesses potential drugs in mid-stage developments to be launched in the near future. The major key players, including Lutris Pharma Ltd., and Hoth Therapeutics, among others, hold the potential to create a significant positive shift in the EGFR Inhibitors-Induced Skin Disorders treatment scenario in the coming years with the launch of potential therapies in the market.

DelveInsight’s “EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the EGFR Inhibitors-Induced Skin Disorders market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The EGFR Inhibitors-Induced Skin Disorders market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

EGFR Inhibitors-Induced Skin Disorders Market

EGFR Inhibitors-Induced Skin Disorders: An Overview

The Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein that regulates multiple cellular processes. The EGFR inhibitor is a class of targeted antitumor agents designed to bind to the EGFR, thereby preventing its activity. The US FDA, the EMA, and the PMDA have approved several drugs in this class, and associated side effects have also been noticed.

The most common side effects of EGFR-targeted therapies are dermatologic toxicities. EGFR inhibitor-mediated dermatologic side effects include an acneiform skin rash, hyperpigmentation, xerotic skin, pruritus, skin fissures, nail changes, and disorders of mucous membranes, eyes, and hair.

EGFR Inhibitors-Induced Skin Disorders Market Key Facts

  • The market size of EGFR Inhibitors-induced Skin Disorders in the 7MM was estimated to be USD 57 million in 2020, which is expected to grow by 2032. 

  • The United States holds the largest market share of EGFR Inhibitors-induced Skin Disorders among the 7MM countries, which accounts for 49.59% (USD 28 million) of the total 7MM market in 2020.

  • Among the EU-5 countries, Germany (USD 5 million) had the highest market share, followed by France (USD 4 million) and Italy (USD 4 million), in 2020.

  • Japan holds the second-largest share of the 7MM EGFR Inhibitors-induced Skin Disorders market with a market size of USD 9 million in 2020.

  • The total number of cases of EGFR Inhibitors-induced Skin Disorders in the 7MM was 106,100+ in 2020, which is likely to increase by 2032.

  • In 2020, the total number of cases of cancer patients on EGFR inhibitors in the US was estimated to be 57,500+. The total number of cases of EGFR Inhibitors-induced Skin Disorders in the US was 37,400+ in 2020.

  • EGFR Inhibitors-Induced Skin Disorders’ current treatment market is limited to topical steroid creams or ointments, local and systemic therapies, and others. Imsidolimab (ANB019) is expected to reach the market by 2025, generating a market size of USD 3 million in the launch year. The current market is mainly based on off-label therapies so it might capture a large market share of current therapies by 2032.

EGFR Inhibitors-Induced Skin Disorders Market 

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted EGFR Inhibitors-Induced Skin Disorders market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the EGFR Inhibitors-Induced Skin Disorders market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

EGFR Inhibitors-Induced Skin Disorders Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

EGFR Inhibitors-Induced Skin Disorders Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR Inhibitors-Induced Skin Disorders market or expected to get launched during the study period. The analysis covers the EGFR Inhibitors-Induced Skin Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the EGFR Inhibitors-Induced Skin Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How EGFR Inhibitors-Induced Skin Disorders Market Will Evolve by 2032 @ 

https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market

EGFR Inhibitors-Induced Skin Disorders Therapeutics Analysis

The Leading Companies in the EGFR Inhibitors-Induced Skin Disorders Therapeutics Market Include:

  • AstraZeneca

  • Pfizer

  • Novartis Pharmaceuticals

  • Janssen Research & Development

  • Yuhan Corporation/

  • Janssen Research & Development

  • Takeda

EGFR Inhibitors-Induced Skin Disorders Emerging Drugs Covered in the Report Include:

  • Imsidolimab (ANB019): AnaptysBio Inc.

  • AC-701 Topical Gel 0.3%: TWi Pharmaceuticals

And many others

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @ 

https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. EGFR Inhibitors-Induced Skin Disorders Competitive Intelligence Analysis

4. EGFR Inhibitors-Induced Skin Disorders Market Overview at a Glance

5. EGFR Inhibitors-Induced Skin Disorders Disease Background and Overview

6. EGFR Inhibitors-Induced Skin Disorders Patient Journey

7. EGFR Inhibitors-Induced Skin Disorders Epidemiology and Patient Population (In the US, EU5, and Japan)

8. EGFR Inhibitors-Induced Skin Disorders Treatment Algorithm, Current Treatment, and Medical Practices

9. EGFR Inhibitors-Induced Skin Disorders Unmet Needs

10. Key Endpoints of EGFR Inhibitors-Induced Skin Disorders Treatment

11. EGFR Inhibitors-Induced Skin Disorders Marketed Products

12. EGFR Inhibitors-Induced Skin Disorders Emerging Drugs and Latest Therapeutic Advances

13. EGFR Inhibitors-Induced Skin Disorders Seven Major Market Analysis

14. Attribute Analysis

15. EGFR Inhibitors-Induced Skin Disorders Market Outlook (In US, EU5, and Japan)

16. EGFR Inhibitors-Induced Skin Disorders Access and Reimbursement Overview

17. KOL Views on the EGFR Inhibitors-Induced Skin Disorders Market

18. EGFR Inhibitors-Induced Skin Disorders Market Drivers

19. EGFR Inhibitors-Induced Skin Disorders Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories